Atara生物治療 ATRA 深 滬
已收盤 05-08 16:00:00 美东时间
8.34
-1.590
-16.01%
華盛通- 最 高9.93
- 今 開9.65
- 成交量 299.15万股
- 最 低 7.85
- 昨 收 9.93
- 總市值 7099.23万
- 52周最高 19.145
- 市盈率 靜 3.24
- 換手率 35.14%
- 52周最低 3.92
- 委 比 10.67%
- 總股本 851.23万
- 歷史最高 1639.00
- 量 比 0.19
- 振 幅 20.95%
- 歷史最低 3.92
- 每 手 1
- 風險率 4.22%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Atara surges after FDA meeting on cell therapy
Atara Biotherapeutics (ATRA) climbed nearly 100% on Thursday after the company announced that a recent meeting with the FDA raised prospects for its cell therapy candidate, tabelecleucel, which was re...
05-08 02:13
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Agilon Health (NYSE:AGL) shares moved upwards by 115.7% to $60.08 duri...
05-08 01:05
Atara Biotherapeutics Reports FDA Alignment On Path Forward For Tab-cel Resubmission Following CRL Meeting
Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and
05-07 20:19
Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx
WALTHAM, Mass., April 01, 2026 -- Ardelyx, Inc. announced the appointment of Rajani Dinavahi, MD, as Chief Medical Officer. Dr. Dinavahi brings over two decades of experience in healthcare and biotechnology, with expertise in immuno-oncology, autoimmune diseases, metabolic disease, nephrology, and transplantation. She previously served as Chief Medical Officer at Atara Biotherapeutics. Ardelyx's president and CEO, Mike Raab, highlighted her scien...
04-01 12:01
Atara Plans FDA Type A Meeting on EBVALLO
The latest update is out from Atara Biotherapeutics ( ($ATRA) ). On March 12, 2...
03-12 20:37
Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast
Mesoblast Limited announced the appointment of Dr. Teresa Montagut as Head of Clinical Development and Medical Affairs, tasked with advancing the company's cell therapy programs for pediatric and adult inflammatory conditions. Dr. Montagut brings extensive experience in medical leadership and cancer immunotherapy development, previously leading programs at Regeneron, Novartis, and Genentech. Mesoblast is focused on developing allogeneic cellular ...
03-11 23:21
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Relmada Therapeutics (NASDAQ:RLMD) stock rose 48.3% to $6.6 during Mon...
03-09 20:05
Atara Biotherapeutics' Pierre Fabre Pharmaceuticals Submits Request To FDA For Type A Meeting About ALLELE Trial
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and
03-03 21:27
BRIEF-Atara Biotherapeutics Provides Regulatory Update On Tabelecleucel
BRIEF-Atara Biotherapeutics Provides Regulatory Update On Tabelecleucel March 3 (Reuters) - Atara Biotherapeutics Inc ATRA.O : ATARA BIOTHERAPEUTICS PROVIDES REGULATORY UPDATE ON TABELECLEUCEL Source text: ID:nBwcf5zT8a Further company coverage: ATRA.O (( Reuters.Briefs@thomsonreuters.com ;))
03-03 21:12
Atara jumps amid report on FDA’s U-turn on cell therapy
Shares of Atara Biotherapeutics (ATRA) climbed on Wednesday after Stat News reported that the U.S. FDA rejected the company’s cell therapy tabelecleucel last month despite its internal reviewers recom...
02-26 02:56
